Cover Image
市场调查报告书

生物相似药的全球市场:收益、市场趋势、成长率、市场占有率分析、预测

Biosimilar Market - Global Revenue, Trends, Growth, Share, Size and Forecast

出版商 Scalar Market Research 商品编码 531375
出版日期 内容信息 英文 102 Pages
商品交期: 最快1-2个工作天内
价格
Back to Top
生物相似药的全球市场:收益、市场趋势、成长率、市场占有率分析、预测 Biosimilar Market - Global Revenue, Trends, Growth, Share, Size and Forecast
出版日期: 2016年10月01日 内容信息: 英文 102 Pages
简介

本报告提供全球生物相似药的市场调查,市场定义和概要,市场的各种影响因素及市场机会分析,法律制度,开发平台分析,各产品类型、用途、地区/主要国家趋势与市场规模的变化与预测,竞争环境,企业简介等汇整数据。

第1章 市场概要

第2章 摘要整理

第3章 市场动态

  • 成长推动因素
  • 阻碍成长要素
  • 市场机会
  • 市场趋势

第4章 产业分析

  • 产业概要
  • 法律规章分析
  • 进入 (Time to Entry) 分析
  • 开发平台分析
  • 价格分析
  • 相关利益者分析

第5章 市场分析、预测:各产品类型

  • 市场概要
  • 市场占有率
  • 收益
  • 出货规模
  • 产品类型
    • 重组糖基化蛋白质
    • 重组非糖基化蛋白质
    • 重组肽

第6章 市场分析、预测:各用途

  • 市场概要
  • 市场占有率
  • 用途
    • 癌症
    • 血液学疾病
    • 感染疾病
    • 自体免疫系疾病
    • 其他

第7章 市场分析、预测:各地区

  • 地区概要
  • 市场占有率
  • 收益
  • 出货规模
  • 北美
    • 各国
      • 美国
      • 加拿大
    • 各产品类型
    • 各用途
  • 欧洲
    • 各国
      • 德国
      • 英国
      • 法国
      • 义大利
      • 其他
    • 各产品类型
    • 各用途
  • 亚太地区
    • 各国
      • 中国
      • 印度
      • 俄罗斯
      • 澳洲
      • 印尼
      • 其他
    • 各产品类型
    • 各用途
  • 中东、非洲
    • 各国
      • 埃及
      • 南非
      • 奈及利亚
      • 其他
    • 各产品类型
    • 各用途
  • 南美
    • 各国
      • 巴西
      • 阿根廷
      • 哥伦比亚
      • 墨西哥
      • 其他
    • 各产品类型
    • 各用途

第8章 竞争环境

  • 市场占有率分析

第9章 主要企业

  • Amgen Inc.
  • AstraZeneca, plc
  • Pfizer Inc.
  • Biocon Ltd.
  • Novartis International AG
  • STADA Arzneimittel AG
  • Teva Pharmaceuticals Industries Ltd.

第10章 总论:SCALAR全方位展望

第11章 附录

目录
Product Code: HC113

Title:
Biosimilars Market
by Product Types (Recombinant Glycosylated Proteins, Recombinant Non-Glycosylated Proteins, Recombinant Peptides), Applications (Oncology, Blood Disorders, Infectious Diseases, Autoimmune Diseases and Others) - Global Revenue, Trends, Growth, Share, Size and Forecast to 2022.

Global Biosimilars Market worth USD 3 billion in 2016 and expected to reach USD 58.40 billion by 2022, at a CAGR of 52.77% from 2016 to 2022.

Our industry experts anticipate that within the biosimilars market, the recombinant glycosylated proteins will be the fastest-growing product segment, growing at a CAGR ranging from 70% to 55%. In addition, oncology will be the largest and the fastest-growing application segment in the market, growing at a CAGR ranging from 80% to 55% by 2022.

KEY BENEFITS OF THE REPORT:

  • In-depth analysis of the key factors is propelling the growth of the global market
  • Detailed analysis of the geographic region that will witness the strongest growth
  • Granular analysis of the current market scenario and the expected market grow

KEY PREMIUM INDUSTRY INSIGHTS:

  • The biosimilars market offers many growth opportunities and driving factors as compared to the restraining factors. It is stated by various research scientists that development of biosimilars will drastically reduce the price of the pharmaceutical drugs.
  • A large number of key companies such as Hospira, Inc., Teva Pharmaceutical, Amgen, and others are in constant efforts to develop biosimilars and are rigorously increasing their research & development expenses on clinical trials to introduce novel biosimilars, driving the market growth.
  • Amgen, Inc. has a strong research pipeline (phase III molecule) for the biosimilar products, such as ABP 501, ABP 980, and ABP 215.
  • The demand for biosimilars is also expected to increase due to the rise in the incidences of the diseases such as cancer, cardiovascular diseases, and such others. For these diseases, biosimilars have proven a promising option for the disease diagnosis and mitigation.
  • Other factors such as rising number of off-patented drugs, positive result of many biosimilar clinical trials and others drive the market growth to a great extent.
  • However, a strict regulatory framework for the biosimilar manufacturers to develop these products restricts the companies from investing in this market, which in turn would hamper the market growth during the future period.

RESEARCH METHODOLOGY:

The research methodology for Scalar Market Research's biosimilars market report utilizes a combination of top-down and bottom-up research formats. Our primary focus on continuous market tracking, rigorous fact-checking, data-triangulation, and multiple layers of quality control ensures high-quality data that can be leveraged for actionable research insights.

  • To know about the assumptions considered for the study

MARKET SEGMENTATION:

This report analyzes the biosimilars market by the following segments:

Biosimilars Market, by Product Types

  • Recombinant Non-Glycosylated Proteins
  • Recombinant Glycosylated Proteins
  • Recombinant Peptides

Biosimilars Market, by Applications

  • Oncology
  • Blood Disorders
  • Infectious Diseases
  • Autoimmune Diseases
  • Others

KEY MARKET PLAYERS:

Key players in the biosimilars market include:

  • Amgen Inc.
  • Astra Zeneca, Plc.
  • Biocon Ltd.
  • Pfizer, Inc.
  • Novartis International AG
  • STADA Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd.

Table of Contents

1.MARKET OVERVIEW

  • 1.1.Definitions
  • 1.2.Market Segmentation
  • 1.3.Research Methodology
  • 1.4.Assumptions

2.EXECUTIVE SUMMARY

3.MARKET DYNAMICS

  • 3.1.Drivers
  • 3.2.Restraints
  • 3.3.Opportunities
  • 3.4.Trends

4.INDUSTRY ANALYSIS

  • 4.1.Industry Overview
  • 4.2.Regulatory Analysis
    • 4.2.1.European Medicines Agency (EMA)
    • 4.2.2.U.S. FDA
    • 4.2.3.India
    • 4.2.4.Latin America
    • 4.2.5.Other Asia-Pacific Countries
  • 4.3.Time to Entry Analysis
  • 4.4.Pipeline Analysis
  • 4.5.Pricing Analysis
  • 4.6.Stakeholders Analysis

5.BIOSIMILARS MARKET, BY PRODUCT TYPES

  • 5.1.Market Overview
  • 5.2.Market Share Segmentation
  • 5.3.Revenue Segmentation
  • 5.4.Product Types
    • 5.4.1.Recombinant Glycosylated Proteins
    • 5.4.2.Recombinant Non-Glycosylated Proteins
    • 5.4.3.Recombinant Peptides

6.BIOSIMILARS MARKET, BY APPLICATIONS

  • 6.1.Market Overview
  • 6.2.Market Share Segmentation
  • 6.3.Applications
    • 6.3.1.Oncology
    • 6.3.2.Blood Disorders
    • 6.3.3.Infectious Diseases
    • 6.3.4.Autoimmune Diseases
    • 6.3.5.Other Diseases

7.BIOSIMILARS MARKET, BY REGIONS

  • 7.1.Geographic Overview
  • 7.2.Market Share Segmentation
  • 7.3.Revenue Segmentation
  • 7.4.Volume Segmentation
  • 7.5.North America
    • 7.5.1.By Regions
      • 7.5.1.1.U.S.
      • 7.5.1.2.Canada
    • 7.5.2.By Product Type
    • 7.5.3.By Applications
  • 7.6.Europe
    • 7.6.1.By Regions
      • 7.6.1.1.Germany
      • 7.6.1.2.U.K
      • 7.6.1.3.France
      • 7.6.1.4.Italy
      • 7.6.1.5.Rest of Europe
    • 7.6.2.By Product Type
    • 7.6.3.By Applications
  • 7.7.Asia-Pacific
    • 7.7.1.By Regions
      • 7.7.1.1.China
      • 7.7.1.2.India
      • 7.7.1.3.Russia
      • 7.7.1.4.Australia
      • 7.7.1.5.Japan
      • 7.7.1.6.South Korea
      • 7.7.1.7.Rest of Asia-Pacific
    • 7.7.2.By Product Type
    • 7.7.3.By Applications
  • 7.8.Middle East& Africa
    • 7.8.1.By Regions
      • 7.8.1.1.Egypt
      • 7.8.1.2.South Africa
      • 7.8.1.3.Nigeria
      • 7.8.1.4.Rest of Middle East& Africa
    • 7.8.2.By Product Type
    • 7.8.3.By Applications
  • 7.9.Latin America
    • 7.9.1.By Regions
      • 7.9.1.1.Brazil
      • 7.9.1.2.Argentina
      • 7.9.1.3.Columbia
      • 7.9.1.4.Mexico
      • 7.9.1.5.Rest of Latin America
    • 7.9.2.By Product Type
    • 7.9.3.By Applications

8.COMPETITIVE LANDSCAPE

  • 8.1.Market Share Analysis

9.KEY MARKET PLAYERS

  • 9.1.Amgen Inc.
    • 9.1.1.Overview
    • 9.1.2.Key Strategies
    • 9.1.3.Recent Developments
  • 9.2.AstraZeneca, plc
    • 9.2.1.Overview
    • 9.2.2.Key Strategies
    • 9.2.3.Recent Developments
  • 9.3.Pfizer Inc.
    • 9.3.1.Overview
    • 9.3.2.Key Strategies
    • 9.3.3.Recent Developments
  • 9.4.Biocon Ltd.
    • 9.4.1.Overview
    • 9.4.2.Key Strategies
    • 9.4.3.Recent Developments
  • 9.5.Novartis International AG
    • 9.5.1.Overview
    • 9.5.2.Key Strategies
    • 9.5.3.Recent Developments
  • 9.6.STADA Arzneimittel AG
    • 9.6.1.Overview
    • 9.6.2.Key Strategies
    • 9.6.3.Recent Developments
  • 9.7.Teva Pharmaceuticals Industries Ltd.
    • 9.7.1.Overview
    • 9.7.2.Key Strategies
    • 9.7.3.Recent Developments

10.LAST WORD: SCALAR 360 DEGREE MARKET PERSPECTIVE

11.APPENDIX

LIST OF TABLES

  • Table 1. Research Methodology
  • Table 2. Assumptions
  • Table 3. Global Biosimilars Market Size (US$ billion), (2016-2022)
  • Table 4. Global Biosimilars Volume (Million Units), (2014-2022)
  • Table 5. EMA Approved Biosimilars
  • Table 6. U.S. FDA Approved Biosimilars
  • Table 7. Approved Biosimilars in India
  • Table 8. Biosimilars Approved, Marketed in Latin America
  • Table 9. Biosimilars Approved, Marketed in Australia
  • Table 10. Time to Entry Analysis (Generics vs. Biologics vs. Biosimilars)
  • Table 11. Time to Market Entry for Biosimilars from EMA's approval
  • Table 12. Top Selling Biologic Products to lose patent in the coming years (Sales in US$ Billion)
  • Table 13. Companies with largest number of Biosimilars in Pipeline (2015)
  • Table 14. Top Biosimilars in Phase 3 Stage of the Development
  • Table 15. Development & Investment Costs (Generics vs. Biologics vs. Biosimilars)
  • Table 16. Pricing of Top Biosimilars Products with Average Market Price(2015)
  • Table 17. Impact of the Growth of Biosimilars Market on Stakeholders
  • Table 18. Global Biosimilars Market Size (US$ billion), By Product Types (2014 - 2022)
  • Table 19. Global Recombinant Glycosylated ProteinsBiosimilars Market Size (US$ billion), By Regions (2014-2022)
  • Table 20. Global Recombinant Non-Glycosylated ProteinsBiosimilars Market Size (US$ billion),By Regions (2014-2022)
  • Table 21. Global Recombinant Peptides Biosimilars Market Size (US$ billion), By Regions (2014-2022)
  • Table 22. Global Biosimilars Market Size (US$ billion), By Applications (2014-2022)
  • Table 23. Global Biosimilars Market for Oncology; Market Size (US$ billion) (2014-2022)
  • Table 24. Global Biosimilars Market for Blood Disorders; Market Size (US$ billion) (2014-2022)
  • Table 25. Global Biosimilars Market for Infectious Diseases; Market Size (US$ billion) (2014-2022)
  • Table 26. Global Biosimilars Market for Autoimmune Diseases; Market Size (US$ billion) (2014-2022)
  • Table 27. Global Biosimilars Market for Other Diseases; Market Size (US$ billion) (2014-2022)
  • Table 28. Biosimilars Market Prospects, by Geography (2016-2022)
  • Table 29. Global Biosimilars Market Size (US$ billion), By Regions (2014-2022)
  • Table 30. Global Biosimilars Market; Market Size, By Major Countries (2014-2022)
  • Table 31. Global Biosimilars Volume (Million Units), (2014-2022)
  • Table 32. Biosimilars Market in North America; Market Size (US$ billion) (2014-2022)
  • Table 33. Biosimilars Market in U.S; Market Size (US$ billion), (2014-2022)
  • Table 34. Biosimilars Market in Canada; Market Size (US$ billion), (2014-2022)
  • Table 35. Biosimilars Market in North America; Market Size (US$ billion), By Product Type (2014-2022)
  • Table 36. Biosimilars Market in North America; Market Size (US$ billion), By Applications (2014-2022)
  • Table 37. Biosimilars Market in Europe; Market Size (US$ billion)
  • Table 38. Biosimilars Market in Germany; Market Size (US$ billion), (2014-2022)
  • Table 39. Biosimilars Market in U.K; Market Size (US$ billion), (2014-2022)
  • Table 40. Biosimilars Market in France; Market Size (US$ billion), (2014-2022)
  • Table 41. Biosimilars Market in Italy; Market Size (US$ billion), (2014-2022)
  • Table 42. Biosimilars Market in Rest of Europe; Market Size (US$ billion), (2014-2022)
  • Table 43. Biosimilars Market in Europe; Market Size (US$ billion), By Product Type (2014-2022)
  • Table 44. Biosimilars Market in Europe; Market Size (US$ billion), By Applications (2014-2022)
  • Table 45. Biosimilars Market in Asia-Pacific; Market Size (US$ billion)
  • Table 46. Biosimilars Market in China; Market Size (US$ billion), (2014-2022)
  • Table 47. Biosimilars Market in India; Market Size (US$ billion), (2014-2022)
  • Table 48. Biosimilars Market in Russia; Market Size (US$ billion), (2014-2022)
  • Table 49. Biosimilars Market in Australia; Market Size (US$ billion), (2014-2022)
  • Table 50. Biosimilars Market in Japan; Market Size (US$ billion), (2014-2022)
  • Table 51. Biosimilars Market in South Korea; Market Size (US$ billion), (2014-2022)
  • Table 52. Biosimilars Market in Rest of Asia-Pacific; Market Size (US$ billion), (2014-2022)
  • Table 53. Biosimilars Market in Asia-Pacific; Market Size (US$ billion), By Product Type (2014-2022)
  • Table 54. Biosimilars Market in Asia-Pacific; Market Size (US$ billion), By Applications (2014-2022)
  • Table 55. Biosimilars Market in Middle East& Africa; Market Size (US$ billion)
  • Table 56. Biosimilars Market in Egypt; Market Size (US$ billion), (2014-2022)
  • Table 57. Biosimilars Market in South Africa; Market Size (US$ billion), (2014-2022)
  • Table 58. Biosimilars Market in Nigeria; Market Size (US$ billion), (2014-2022)
  • Table 59. Biosimilars Market in Rest of Middle East& Africa; Market Size (US$ billion), (2014-2022)
  • Table 60. Biosimilars Market in Middle East & Africa; Market Size (US$ billion), By Product Type (2014-2022)
  • Table 61. Biosimilars Market in Middle East & Africa; Market Size (US$ billion), By Applications (2014-2022)
  • Table 62. Biosimilars Market in Latin America; Market Size (US$ billion)
  • Table 63. Biosimilars Market in Brazil; Market Size (US$ billion), (2014-2022)
  • Table 64. Biosimilars Market in Argentina; Market Size (US$ billion), (2014-2022)
  • Table 65. Biosimilars Market in Columbia; Market Size (US$ billion), (2014-2022)
  • Table 66. Biosimilars Market in Mexico; Market Size (US$ billion), (2014-2022)
  • Table 67. Biosimilars Market in Rest of Latin America; Market Size (US$ billion), (2014-2022)
  • Table 68. Biosimilars Market in Latin America; Market Size (US$ billion), By Product Type (2014-2022)
  • Table 69. Biosimilars Market in Latin America; Market Size (US$ billion), By Applications (2014-2022)
  • Table 70. Acronyms

LIST OF FIGURES

  • Figure 1. Research Methodology
  • Figure 2. Global Biosimilars Market Share(%), By Geography (2015 & 2022)
  • Figure 3. Global Biosimilars Market Share(%), By Product Type (2015 & 2022)
  • Figure 4. Global Biosimilars Market Share(%), By Applications (2015 & 2022)
  • Figure 5. Product Roadmap
  • Figure 6. Market Attractiveness forBiosimilars Set-up
  • Figure 7. Number of Biological Products going off-patent by 2022 in U.S.
  • Figure 8. Estimated sales of Biological Products going off-patent by 2022 in U.S (in Billion)
  • Figure 9. Biosimilars by Stage of Development (2016)
  • Figure 10. Number (in percentage) of Biosimilar Companies, By Geography (2016)
  • Figure 11. Global Biosimilars Market: Prescriber Acceptancevs. Patient Acceptance, By Geography (2015)
  • Figure 12. Market Attractiveness for different Biosimilars Product Segments
  • Figure 13. Global Biosimilars Market, By Product Segments: Market Size vs. Market Penetration(2015)
  • Figure 14. Global Biosimilars Market Share(%), By Product Type (2015 & 2022)
  • Figure 15. Global Biosimilars Market Size (US$ billion), By Product Types (2014-2022)
  • Figure 16. Global Recombinant Glycosylated ProteinsBiosimilars Market Size (US$ billion), By Regions (2015 & 2022)
  • Figure 17. Global Recombinant Non-Glycosylated ProteinsBiosimilars Market Size (US$ billion), By Regions (2015 & 2022)
  • Figure 18. Global Recombinant PeptidesBiosimilars Market Size (US$ billion), By Regions (2015 & 2022)
  • Figure 19. Global Biosimilars Market Size (US$ billion), By Applications (2015)
  • Figure 20. Global Biosimilars Market Share (%), By Applications (2015 & 2022)
  • Figure 21. Global Biosimilars Market Size (US$ billion), By Applications (2015 vs.2022)
  • Figure 22. Global Biosimilars Market for Oncology; Market Size (US$ billion) (2015 & 2022)
  • Figure 23. Global Biosimilars Market for Blood Disorders; Market Size (US$ billion) (2015 & 2022)
  • Figure 24. Global Biosimilars Market for Infectious Diseases; Market Size (US$ billion) (2015 & 2022)
  • Figure 25. Global Biosimilars Market for Autoimmune Diseases; Market Size (US$ billion) (2015 & 2022)
  • Figure 26. Global Biosimilars Market for Other Diseases; Market Size (US$ billion) (2015 & 2022)
  • Figure 27. Global Biosimilars Market Share (%), By Major Regions(2015 & 2022)
  • Figure 28. Top 5 Countries, By Market Share (%) (2015)
  • Figure 29. Top 5 Countries, By Market Share (%) (2022)
  • Figure 30. Biosimilars Market in North America; Snapshot (2015)
  • Figure 31. Biosimilars Market in North America; Market Size (US$ billion)(2014-2022)
  • Figure 32. Biosimilars Market in North America; Market Size (US$ billion),By Product Type (2014-2022)
  • Figure 33. Biosimilars Market in North America; Market Size (US$ billion),By Applications (2016 vs.2022)
  • Figure 34. Biosimilars Market in Europe; Snapshot (2015)
  • Figure 35. Biosimilars Market in Europe; Market Size (US$ billion)(2014-2022)
  • Figure 36. Biosimilars Market in Europe; Market Size (US$ billion),By Product Type (2014-2022)
  • Figure 37. Biosimilars Market in Europe; Market Size (US$ billion),By Applications (2016 vs.2022)
  • Figure 38. Biosimilars Market in Asia-Pacific; Snapshot (2015)
  • Figure 39. Biosimilars Market in Asia-Pacific; Market Size (US$ billion)(2014-2022)
  • Figure 40. Biosimilars Market in Asia-Pacific; Market Size (US$ billion),By Product Type (2014-2022)
  • Figure 41. Biosimilars Market in Asia-Pacific; Market Size (US$ billion),By Applications (2016 vs.2022)
  • Figure 42. Biosimilars Market in Middle East& Africa; Snapshot (2015)
  • Figure 43. Biosimilars Market in Middle East& Africa; Market Size (US$ billion) (2014-2022)
  • Figure 44. Biosimilars Market in Middle East& Africa; Market Size (US$ billion),By Product Segments(2014-2022)
  • Figure 45. Biosimilars Market in Middle East& Africa; Market Size (US$ billion),By Applications (2016 vs.2022)
  • Figure 46. Biosimilars Market in Middle Latin America; Snapshot (2015)
  • Figure 47. Biosimilars Market in Latin America; Market Size (US$ billion) (2014-2022)
  • Figure 48. Biosimilars Market in Latin America; Market Size (US$ billion),By Product Type(2014-2022)
  • Figure 49. Biosimilars Market in Latin America; Market Size (US$ billion),By Applications (2016 vs.2022)
  • Figure 50. Market Share (%) Analysis of Major Players, 2015
Back to Top